Warning letter
Louisiana Substance Abuse Clinic Inc.: warning letter of May 9, 2000
FDA warning letter UCM068417 · New Orleans District Office
Key facts
| Reference number | UCM068417 |
|---|---|
| Company | Louisiana Substance Abuse Clinic Inc. |
| Subject | Narcotic Treatment Standards Violations |
| Issue date | May 9, 2000 |
| Posted date | May 9, 2000 |
| Issuing office | New Orleans District Office |
| Product type | Drugs |
| Country | 3 |
| Inspection city | Tallulah |
| Inspection ZIP | 71282 |
| Inspection start date | Feb 8, 2000 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: